The PANSS is currently the most established scale in patients with schizophrenia. For example in the high impact journal "Schizophrenia Bulletin" Kay's publication on the Positive and Negative ...

Participants randomized to the novel combination therapy had significantly reduced Positive and Negative Syndrome Scale (PANSS) total scores over 5 weeks compared with those on placebo (−20.6 vs ...

It appears shareholders were spooked by the size of the reduction in PANSS – a 7.5 improvement on placebo and an 18.2-point fall from baseline – compared to similarly-acting rival therapies in ...

finding that patients with higher scores on the Positive and Negative Syndrome Scale (PANSS) were more likely to experience manic symptoms. This correlation proved particularly strong for positive ...

In the 81-patient phase 1b trial, CVL-231 was able to achieve significant reductions in the Positive and Negative Syndrome Scale (PANSS) of schizophrenia symptoms, compared to both placebo and ...

Otsuka Pharmaceutical Europe Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the European Commission (EC) has approved Rxulti® (brexpiprazole) for the treatment of schizophrenia in ...

Otsuka Pharmaceutical Europe and Lundbeck have announced that the European Commission has approved Rxulti (brexpiprazole) for ...

The European Commission (EC) has approved Danish CNS specialist Lundbeck (LUND: CO) and Otsuka Europe’s Rxulti ...

Background: The PANSS (Positive and Negative Syndrome Scale) is one of the most important rating instruments for patients with schizophrenia. Nevertheless, there is a long and ongoing debate in ...